164 related articles for article (PubMed ID: 26309071)
21. 340B Drug Pricing Program: The Expansion and Its Effect on Cancer Care.
Fauer A; Friese CR
Clin J Oncol Nurs; 2019 Apr; 23(2):217-219. PubMed ID: 30880808
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
[TBL] [Abstract][Full Text] [Related]
23. American pharmaceutical prices.
Alagona P
Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(4):58. PubMed ID: 12592980
[No Abstract] [Full Text] [Related]
24. Exploring the rise in American pharmaceutical prices.
Marwaha A
Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(2):11-5. PubMed ID: 12099112
[No Abstract] [Full Text] [Related]
25. The Canadians are killing us.
Struble RA
Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(4):58-9. PubMed ID: 12592981
[No Abstract] [Full Text] [Related]
26. Pharmacoeconomics in the era of individualized medicine.
Waldman SA; Terzic A
Clin Pharmacol Ther; 2008 Aug; 84(2):179-82. PubMed ID: 18679176
[No Abstract] [Full Text] [Related]
27. Pharmacoeconomic evaluation to assist prescription drug pricing: a US perspective on an international issue.
Bonk RJ; McGhan WF
Pharmacoeconomics; 1993 Aug; 4(2):73-6. PubMed ID: 10146968
[No Abstract] [Full Text] [Related]
28. Medicare and drug pricing.
Iglehart JK
N Engl J Med; 2003 Apr; 348(16):1590-7. PubMed ID: 12700381
[No Abstract] [Full Text] [Related]
29. Optimum cancer care--an unaffordable goal?
Ludwig H
Lancet Oncol; 2004 Sep; 5(9):529-30. PubMed ID: 15337480
[No Abstract] [Full Text] [Related]
30. PhRMA sues on 340B orphans.
Lee J
Mod Healthc; 2013 Oct; 43(40):17. PubMed ID: 24340726
[No Abstract] [Full Text] [Related]
31. Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014.
Dusetzina SB
JAMA Oncol; 2016 Jul; 2(7):960-1. PubMed ID: 27123993
[No Abstract] [Full Text] [Related]
32. [Pharmacoeconomic aspects of oral cytostatic agents].
Poquet Jornet JE; Carrera-Hueso FJ; Gasent Blesa JM; Peris Godoy M
Farm Hosp; 2011 May; 35 Suppl 2():25-31. PubMed ID: 22445506
[TBL] [Abstract][Full Text] [Related]
33. [Pharmacoeconomic aspects of breast cancer management].
Kolbin AS; Zagorodnikova KA
Vopr Onkol; 2011; 57(5):604-8. PubMed ID: 22238930
[No Abstract] [Full Text] [Related]
34. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
35. Expensive cancer therapies: unintended effects.
Delude CM
J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
[No Abstract] [Full Text] [Related]
36. [Pharmacoeconomics and cost of cancer drugs].
Camps Herrero C; Caballero Díaz C; Blasco Cordellat A
Farm Hosp; 2010 Mar; 34 Suppl 1():12-5. PubMed ID: 20920852
[TBL] [Abstract][Full Text] [Related]
37. Keynote comment: Cancer drug pricing in the USA.
Johnson DH
Lancet Oncol; 2006 Jun; 7(6):444-5. PubMed ID: 16750490
[No Abstract] [Full Text] [Related]
38. Oral/infusion cancer drug parity begins to raise health plan costs.
Carroll J
Manag Care; 2012 Jan; 21(1):7-8. PubMed ID: 22334937
[No Abstract] [Full Text] [Related]
39. Pharmacy team involvement in navigating the revenue cycle for high-cost medications in patients with cancer.
Shank BR; Nguyen PAA; Pherson EC
Am J Manag Care; 2017 Oct; 23(12 Spec No.):SP470-SP473. PubMed ID: 29087665
[No Abstract] [Full Text] [Related]
40. Can treatment costs be tamed?
Malakoff D
Science; 2011 Mar; 331(6024):1545-7. PubMed ID: 21436438
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
